Home Impact of Nautilus on Biotech and Pharmaceutical Patents
 

Keywords :   


Impact of Nautilus on Biotech and Pharmaceutical Patents

2015-11-16 21:13:08| Biotech - Topix.net

In Nautilus, Inc. v. Biosig Instruments, Inc. , 134 S. Ct. 2120 , the Supreme Court rejected the Federal Circuit's "insolubly ambiguous" standard for determining whether a patent claim meets the definiteness requirement under 35 U.S.C. 112, 2, and held that "a patent is invalid for indefiniteness if its claims, read in light of the specification delineating the patent, and the prosecution history, fail to inform, with reasonable certainty, those skilled in the art about the scope of the invention."

Tags: impact patents pharmaceutical biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
17.06Atlantic Tropical Weather Outlook
17.06Eastern North Pacific Tropical Weather Outlook
17.06Too much of a good thing? Spain's green energy can exceed demand
16.06Eastern North Pacific Tropical Weather Outlook
16.06Atlantic Tropical Weather Outlook
16.06Eastern North Pacific Tropical Weather Outlook
16.06Atlantic Tropical Weather Outlook
16.06Weekly Recap: U.S. House Approves WIPPES Legislation, Drylock Holds Private Label Academy & More
More »